Navigation Links
Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Date:4/24/2008

PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Morgan Stanley Global Healthcare Unplugged Conference being held from April 30, 2008 to May 2, 2008 at the Ritz-Carlton Key Biscayne in Miami, Florida. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company and participate in a discussion moderated by Morgan Stanley representatives on Wednesday, April 30, 2008 at 3:40 PM (ET) in the Plaza Ballroom.

To access a simultaneous webcast of Mr. Price's overview and discussion via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation, if any, will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
2. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
3. Pharmasset Receives $10 Million of Working Capital
4. Pharmasset Appoints Herbert J. Conrad as a Director
5. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
6. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset Reports Fiscal Year End 2007 Financial Results
9. Pharmasset Appoints Michael Rogers as Chief Development Officer
10. Pharmasset to Present at Three Investor Conferences in November 2007
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014 /PRNewswire-iReach/ -- ... agreement with FORMA Therapeutics, Inc., to provide access ... proprietary fragment-based lead discovery platform for novel small ... excited about the opportunity to work with FORMA ... of epigenetics and protein homeostasis. FORMA Therapeutics, decision ...
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 ... IRB services, has been awarded accreditation by the ... for its Lean Six Sigma Deployment Program. ... waste and improve performance. , Quorum’s Lean Six ... the Accredited Deployment Program designation. The designation is ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The prestigious ... of Congress was recently awarded to Juliana Hillis and ... MA, for their project, “From an Egg, Everything: America’s ... 3,000 final entries for the National History Day program ... 300 historians and educators in Washington, D.C. , The ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... A ... into specific T cell lineages to the activity of a single gene encoding a transcription ... the development of blood cells lineages. , ... (PRWeb UK) July 1, 2010 -- A research team in Japan has linked ...
... , WALTHAM, Mass. , July 1 ... multi-year collaborative agreement with Roche to apply X-Chem,s proprietary ... several of Roche,s high-value therapeutic targets. As part of ... research payments, success-based discovery milestones, and technology access fees. ...
... CLEVELAND , June 30 RSB Spine, LLC, a medical ... of degenerative disc disease, today announced a 50% sales increase for the ... sequentially. Additionally, the company reported record sales for the month of June. ... RSB Spine Chief Executive ...
Cached Biology Technology:The Last Checkpoint to T Cell Fate 2X-Chem and Roche Enter Into Drug Discovery Collaboration and License Agreement 2
(Date:7/29/2014)... different types of cell, including sperm, bacteria and ... flagella. These protrusions, about one-hundredth of a millimetre ... through fluid. Similar, shorter structures called cilia are ... they perform roles such as moving liquids over ... remarkably versatile: they transport mucus and expel pathogens ...
(Date:7/28/2014)... of two additional coral communities showing signs of damage from ... the 2010 spill in the Gulf of Mexico. The discovery ... of biology at Penn State University. A paper describing this ... the Gulf of Mexico will be published during the last ... the journal Proceedings of the National Academy of Sciences ...
(Date:7/28/2014)... Millions of people in the United States have a ... It can be painful and may even require surgery ... skeletal muscle wasting and, in turn, limb amputation. , ... Houston (UTHealth) Medical School, scientists tested a non-surgical preventative ... it was associated with increased blood circulation. Their ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... A Senior Design team at Stevens Institute of Technology ... often arise during thoracic surgeries. Five undergraduate Biomedical Engineering ... issues of existing catheter design and introduces a potentially ... 21, the efforts of the Stevens Innovative Fluid Extraction ...
... Los Angeles, Calif., May 22, 2011Some men of African ... cancer, according to research conducted at the Keck School of ... genome-wide association study, published in the journal Nature Genetics ... prostate cancer in men of African descent, who tend to ...
... automated microfluidic cell culture platform to monitor the growth, ... (HSCs) at the single cell level. This ... culture conditions simultaneously and to gain new insights on ... "The ability to perform massively parallel cultures of single ...
Cached Biology News:Stevens thoracic catheter senior design team takes 1st place at regional ISPE competition 2Stevens thoracic catheter senior design team takes 1st place at regional ISPE competition 3USC research determines apparent genetic link to prostate cancer in African-American men 2UBC-led team develops platform to monitor hematopoietic stem cells 2